Profilaxis de sangrado gastrointestinal en paciente crítico
DOI:
https://doi.org/10.18270/rce.v8i8.552Palabras clave:
prevencion y control, Hemorragia gastrointestinal, Enfermedad criticaResumen
Las úlceras gástricas que se presentan en pacientes críticos generan un daño exponencial y constante en la mucosa gástrica, que aumenta la incidencia de hemorragias gastrointestinales clínicamente significativas, lo cual prolonga los periodos de estancia hospitalaria en una unidad de cuidado intensivo (UCI) e incrementa el riesgo de muerte. Para prevenir este tipo de complicaciones, se pueden utilizar varias opciones farmacológicas; sin embargo, no existe un consenso que permita establecer cuál de todas las opciones existentes es la mejor decisión terapéutica para estos pacientes, razón por la cual es pertinente realizar una revisión narrativa de la literatura que contribuya a la toma de decisiones por parte de los médicos tratantes.
Descargas
Referencias bibliográficas
Stollman N, Metz DC. Pathophysiology and prophylaxis of stress ulcer in intensive care unit patients. J Crit Care. 2005; 20(1): 35-45.
Solouki M, Marashian SM, Kouchak M, Mokhtari M, Nasiri E. Comparison between the preventive effects of ranitidine and omeprazole on upper gastrointestinal bleeding among ICU patients. Tanaffos. 2009; 8(4): 37-42.
Phillips JO, Olsen KM, Rebuck JA, Rangnekar NJ, Miedema BW, Metzler MH. A randomized, pharmacokinetic and pharmacodynamic, cross-over study of duodenal or jejunal administration compared to nasogastric administration of omeprazole suspension in patients at risk for stress ulcers. Am J Gastroenterol. 2001; 96(2): 367-72.
Beejay U, Wolfe MM. Acute gastrointestinal bleeding in the intensive care unit: The gastroenterologist’s perspective. Gastroenterol Clin North Am. 2000; 29(2): 309-36.
Cook DJ, Fuller HD, Guyatt GH, Marshall JC, Leasa D, Hall R, et al. Risk factors for gastrointestinal bleeding in critically ill patients. N Engl J Med. 1994; 330(6): 377-81.
Ali T, Harty RF. Stress-induced ulcer bleeding in critically ill patients. Gastroenterol Clin North Am. 2009; 38(2): 245-65.
Klebl FH, Schölmerich J. Therapy insight: prophylaxis of stress-induced gastrointestinal bleeding in critically ill patients. Nature Clinical Practice Gastroenterology and Hepatology. 2007; 4(10): 562-70.
Delgadillo V, Londoño D, Alvarado J. Incidencia de sangrado digestivo en la UCI del Hospital Universitario San Ignacio. Acta Médica Colombiana. 2009; 34(2).
Herzig SJ, Howell MD, Ngo LH, Marcantonio ER. Acid-suppressive medication use and the risk for hospital-acquired pneumonia. JAMA. 2009; 301(20): 2120-8.
Duerksen DR. Stress-related mucosal disease in critically ill patients. Bailliere’s Best Practice and Research in Clinical Gastroenterology. 2003; 17(3): 327-44.
Pilkington KB, Wagstaff MJD, Greenwood JE. Prevention of gastrointestinal bleeding due to stress ulceration: A review of current literature. Anaesth Intensive Care. 2012; 40(2): 253-9.
Spirt MJ. Stress-related mucosal disease: Risk factors and prophylactic therapy. Clin Ther. 2004; 26(2): 197-213.
Mutlu GM, Mutlu EA, Factor P. GI complications in patients receiving mechanical ventilation. Chest. 2001; 119(4): 1222-41.
Fennerty MB. Pathophysiology of the upper gastrointestinal tract in the critically ill patient: Rationale for the therapeutic benefits of acid suppression. Crit Care Med. 2002; 30 Suppl 6: S351-5.
Metz DC. Preventing the gastrointestinal consequences of stress-related mucosal disease. Curr Med Res Opin. 2005; 21(1): 11-8.
Quenot J-, Thiery N, Barbar S. When should stress ulcer prophylaxis be used in the ICU? Curr Opin Crit Care. 2009; 15(2): 139-43.
Vincent-Smith L, Sinclair D. Acute gastrointestinal haemorrhage. Anaesthesia and Intensive Care Medicine. 2006; 7(4): 124-7.
Levy MJ, Seelig CB, Robinson NJ, Ranney JE. Comparison of omeprazole and ranitidine for stress ulcer prophylaxis. Dig Dis Sci. 1997; 42(6): 1255-9.
Reintam A, Parm P, Kitus R, Kern H, Starkopf J. Gastrointestinal symptoms in intensive care patients. Acta Anaesthesiol Scand. 2009; 53(3): 318-24.
Cook D, Guyatt G, Marshall J, Leasa D, Fuller H, Hall R et al. A comparison of sucralfate and ranitidine for the prevention of upper gastrointestinal bleeding in patients requiring mechanical ventilation. N Engl J Med. 1998; 338(12): 791-7.
Bardou M, Martin J, Barkun A. Intravenous proton pump inhibitors: an evidence-based review of their use in gastrointestinal disorders. Drugs. 2009; 69(4): 435-48.
Wallace J, Sharkey K. Pharmacotherapy of gastric acidity, peptic ulcers and gastroesophageal reflux disease. In: Goodman & Gilman’s. The pharmacological basis of therapeutics. 12th ed. San Diego: McGraw-Hill Companies; 2011. p. 1309-22.
Katzung B, Masters S, Trevor A. Drugs used in the treatment of gastrointestinal diseases. In: Basic and clinical pharmacology. 11th ed. United States: McGraw-Hill Companies; 2010. p. 1008-24.
Berardi R, Fugit R. Peptic ulcer disease. In: Pharmacotherapy. A pathophysiologic approach. 8th ed. United States: McGraw-Hill Companies; 2011. p. 717-34.
Espugles, JV. Flórez, J. Farmacología de la secreción ácida gástrica y de la ulceración mucosa digestiva. En: Farmacología humana. 3ª ed. Barcelona: Editorial Masson; 1997. p. 757-84.
Pisegna JR. Pharmacology of acid suppression in the hospital setting: Focus on proton pump inhibition. Crit Care Med. 2002; 30 Suppl 6: S356-61.
Armstrong TA, Coursin DB, Devlin J, Duke JS, Fish D, Gonzalez ER, et al. ASHP therapeutic guidelines on stress ulcer prophylaxis. American Journal of Health-System Pharmacy. 1999; 56(4): 347-79.
Dial S, Alrasadi K, Manoukin C, Huang A, Menzies D. Risk of clostridium difficile diaarhea among hospital inpatients prescribed proton pump inhibitors: Cohort and case-control studies. CMAJ. 2004; 171(1): 33-8.
Spirt MJ, Stanley S. Update on stress ulcer prophylaxis in critically ill patients. Crit Care Nurse. 2006; 26(1):1 8-28.
Phillips JO, Metzter MH, Huckfeldt RE, Olsen K. A multicenter, prospective, randomized clinical trial of continuous infusion I.V. ranitidine vs. omeprazole suspension in the prophylaxis of stress ulcers. Crit Care Med. 1998; 26:101A.
Jung R, MacLaren R. Proton-pump inhibitors for stress ulcer prophylaxis in critically III patients. Ann Pharmacother. 2002; 36(12): 1929-37.
Gratrix AP, Enright SM, O’Beirne HA. A survey of stress ulcer prophylaxis in intensive care units in the UK [15]. Anaesthesia. 2007; 62(4): 421-2.
Barkun AN, Bardou M, Pham CQD, Martel M. Proton pump inhibitors vs. histamine 2 receptor antagonists for stress-related mucosal bleeding prophylaxis in critically ill patients: A meta-analysis. Am J Gastroenterol. 2012; 107(4): 507-20.
Martin J, Connelly S, Tsui E, Shortridge L, Bainbridge D, Cheng D. Proton pump inhibitors versus H2-Receptor antagonists for stress ulcer prophylaxis in mechanically ventilated intensive care patients: A meta-Analysis. Gastroenterolog. 2009. 136 (5 Suppl 1): A-636.
Pongprasobchai S, Kridkratoke S, Nopmaneejumruslers C. Proton pump inhibitors for the prevention of stress-related mucosal disease in critically-ill patients: A meta-analysis. Journal of the Medical Association of Thailand. 2009; 92(5): 632-7.
Pitimana-aree S, Forrest D, Brown G, Anis A, Wang X-, Dodek P. Implementation of a clinical practice guideline for stress ulcer prophylaxis increases appropriateness and decreases cost of care. Intensive Care Med. 1998; 24(3): 217-23.
Geus WP. Are there indications for intravenous acid-inhibition in the prevention and treatment of upper GI bleeding? Scandinavian Journal of Gastroenterology, Supplement. 2000; 35(232): 10-20.
Welage LS. Overview of pharmacologic agents for acid suppression in critically ill patients. American Journal of Health-System Pharmacy. 2005; 62 Suppl. 2: S4-S10.
Spirt MJ. Stress-related mucosal disease. Curr Treat Options Gastroenterol. 2003; 6: 135-45.
Mulla H, Peek G, Upton D, Lin E, Loubani M. Plasma aluminum levels during sucralfate prophylaxis for stress ulceration in critically ill patients on continuous venovenous hemofiltration: A randomized, controlled trial. Crit Care Med. 2001; 29(2): 267-71.
Harty RF, Ancha HB. Stress ulcer bleeding. Current treatment options in gastroenterology 2006; 9(2): 157-66.
Fennessy GJ, Warrillow SJ. Gastrointestinal problems in intensive care. Anaesthesia and Intensive Care Medicine. 2012; 13(4): 152-7.
Raff T, Germann G, Hartmann B. The value of early enteral nutrition in the prophylaxis of stress ulceration in the severely burned patient. Burns. 1997; 23(4): 313-8.
Marik PE, Vasu T, Hirani A, Pachinburavan M. Stress ulcer prophylaxis in the new millennium: A systematic review and meta-analysis. Crit Care Med. 2010; 38(11): 2222-8.
Hanisch EW, Encke A, Naujoks F, Windolf J. A randomized, double-blind trial for stress ulcer prophylaxis shows no evidence of increased pneumonia. Am J Surg. 1998; 176(5): 453-7.
Yildizdas D, Yapicioglu H, Levent Yilmaz H. Occurrence of ventilator-associated pneumonia in mechanically ventilated pediatric intensive care patients during stress ulcer prophylaxis with sucralfate, ranitidine, and omeprazole. J Crit Care. 2002; 17(4): 240-5.
Devlin JW, Claire KS, Dulchavsky SA, Tyburski JG. Impact of trauma stress ulcer prophylaxis guidelines on drug cost and frequency of major gastrointestinal bleeding. Pharmacotherapy. 1999; 19(4 I): 452-60.
Erstad BL, Camamo JM, Miller MJ, Webber AM, Fortune J. Impacting cost and appropriateness of stress ulcer prophylaxis at a university medical center. Crit Care Med. 1997; 25(10): 1678-84.
Mostafa G, Sing RF, Matthews BD, Pratt BL, Norton HJ, Heniford BT. The economic benefit of practice guidelines for stress ulcer prophylaxis. Am Surg. 2002; 68(2): 146-50.
Barkun AN, Adam V, Martel M, Marc B. Cost-effectiveness analysis: Stress ulcer bleeding prophylaxis with proton pump inhibitors, H2 receptor antagonists. Value in Health. 2013; 16(1): 14-22.
Daley RJ, Rebuck JA, Welage LS, Rogers FB. Prevention of stress ulceration: Current trends in critical care. Crit Care Med. 2004; 32(10): 2008-13.
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor
La Revista Colombiana de Enfermeríade la Facultad de Enfermería de la Universidad El Bosque es una publicación científica, de acceso abierto, y que permite la consulta, lectura, copia, distribución y exhibición de los textos completos de sus artículos sin costo alguno para los usuarios, esto en aras de fomentar un mayor intercambio de conocimiento global, siempre y cuando se dé testimonio de la autoría del mismos y no se busque la obtención de beneficios comerciales por parte de terceros. Ni la Revista ni la Universidad asumen responsabilidad alguna por los puntos de vista expresados por los autores. Los nombres de equipos, materiales y productos manufacturados, incluyendo fármacos que eventualmente puedan mencionarse, no implican recomendación ni propaganda para su uso y sólo se mencionan como identificación genérica.
Los autores ceden sus derechos patrimoniales a la revista. Los manuscritos se publican bajo una Creative Commons Attribution License que permite a otros compartir el trabajo con un reconocimiento de la autoría del trabajo y la publicación inicial en esta revista.
